Results 251 to 260 of about 280,725 (312)

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Is the combination of Myelodysplastic syndromes and pulmonary fibrosis accidental or inevitable? [PDF]

Multidiscip Respir Med
He Y, Li Y, Wang Y, Zhang J, Chen H, Chen J, Zhao Y.   +6 more
europepmc   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, EarlyView.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source

Immunopeptidome profiling in pulmonary fibrosis provides a platform for identifying therapeutic targets. [PDF]

Nat Immunol
Bai Z, Lan T, Hong W, Que H, Zhu M, Xiao X, Wan D, Ai J, Huang S, Wang J, Hong Q, Liu Y, Xiao C, Zhao C, Wang X, Zhang X, Yang T, Xu H, Dai L, Powell CA, Richeldi L, Luo F, Dong H, Yuan Y, Pu Q, Wei X.   +25 more
europepmc   +1 more source

Targeting the senescence‒autophagy axis via p16^INK4a inhibition alleviates pulmonary fibrosis. [PDF]

Signal Transduct Target Ther
Yoo YJ, Zhang M, Jin SH, Lee YR, Jin H, Doan TP, Kim S, Choi S, Park EJ, Na S, Lee Y, Sun J, Cho J, Cho NC, Park SY, Oh WK, Lee YS.   +16 more
europepmc   +1 more source

Mechanistic insights and therapeutic potential of sphingosine‑1‑phosphate in the development of pulmonary fibrosis (Review). [PDF]

Mol Med Rep
Qin Y, Tang C, Tan S, Liu G.
europepmc   +1 more source

Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis. [PDF]

Front Immunol
Sotiropoulou V, Sampsonas F, Vasarmidi E, Antoniou K, Gogali A, Kostikas K, Drakopanagiotakis F, Steiropoulos P, Margaritopoulos G, Porpodis K, Daniil Z, Tomos I, Papanikolaou I, Tzilas V, Loukides S, Tzouvelekis A.   +15 more
europepmc   +1 more source

The Mechanism of Oxidative Stress in Pulmonary Fibrosis and Research Progress. [PDF]

Antioxidants (Basel)
Xu D, Wang Q, Lyu M, Huang C, Yuan X, Chen X, Huang Y.   +6 more
europepmc   +1 more source